Accessibility Menu
GT Biopharma logo

GT Biopharma(NASDAQ) GTBP

Market Cap$13.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1983)-100%
5 Year-100%
1 Year-83%
1 Month-22%
$0.30
-2.97%
-0.01Today
GT Biopharma last closing stock price
MetricPriceDate
Last closeUSD 0.302026-08-12
GT Biopharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.85%USD 0.322026-08-05
1 month-22.08%USD 0.392026-07-13
3 month-31.17%USD 0.442026-05-14
Year to date-61.53%USD 0.792025-12-31
1 year-82.73%USD 1.752025-08-12
3 year-96.5%USD 8.642023-08-11
5 year-99.9%USD 300.302021-08-13
Since inception-100%USD 937,500,000.001983-10-18

GT Biopharma Financials at a Glance

Market Cap

$13.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$47.73M

EPS (TTM)

-$14.40

P/E Ratio

-0.02

Dividend

$0.00

Beta (Volatility)

1.07 (Average)

Price

$0.30

Volume

8,457.327

Open

$0.32

Previous Close

$0.30

Daily Range

$0.30 - $0.32

52-Week Range

$0.26 - $1.70

Estimated Earnings Date

Aug 13, 2026

GTBP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About GT Biopharma

GT Biopharma develops medicines that help the body’s immune system fight cancer. Its main products aim to treat blood cancers and some solid tumors. These treatments are designed for patients with limited options, such as those with relapsed leukemia.

Lab Bench to Bedside: What GT Biopharma Makes

  • TriKE Platform: Fusion proteins that activate natural killer (NK) cells to target cancer; 0% of revenue as of Q1 2025.
  • GTB-3650: Next-generation TriKE for relapsed/refractory acute myeloid leukemia (AML) and high-grade myelodysplastic syndromes (MDS); 0% of revenue.
  • GTB-5550: Preclinical TriKE for B7-H3 positive solid tumors; 0% of revenue.
  • GTB-7550: Preclinical TriKE for autoimmune diseases like lupus, targeting CD19+ B cells; 0% of revenue.
  • Research Partnerships: Collaborations with universities and biotech firms to develop new cancer therapies; 0% of revenue.

Plot Twists: Growth and Expansion Moves

  • Entered co-development partnership with Altor BioScience for cancer therapies (year not specified).
  • Secured exclusive license and research agreements with University of Minnesota (2023, amended 2024).
  • Advanced GTB-3650 into Phase 1 clinical trial after FDA clearance in June 2024.
  • Raised $5.45 million in May 2025 through private placement and secured up to $20 million in additional equity funding.
  • Transitioned to fully remote operations as of July 2024.

Why GT Biopharma Is a Bit Different

GT Biopharma’s technology uses the body’s own immune cells, aiming for fewer side effects than some cancer treatments. Its platform can be adapted quickly for different cancer types. The company relies on academic partnerships for research and manufacturing support.

Five Things You Need to Know

  • No revenue reported for Q1 2025, Q1 2024, or Q1 2023.
  • Net loss was $776,000 in Q1 2025, a 66% improvement from Q1 2024.
  • Operating expenses fell 37% to $1.93 million in Q1 2025.
  • Cash and cash equivalents were $2.37 million as of March 31, 2025.
  • Company faces going concern risk and possible Nasdaq delisting due to low equity.

Bottom Line

GT Biopharma remains a pre-commercial biotech focused on immune-based cancer therapies. The company’s future depends on clinical progress and securing new funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1

CEO

Michael Breen

Website

www.gtbiopharma.com

Headquarters

San Francisco, CA 94104, US

GTBP Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-901.32%

Return on Capital

-214.65%

Return on Assets

-477.53%

Earnings Yield

-50.00%

Dividend Yield

0.00%

Payout Ratio

-0.48%

Stock Overview

Market Cap

$13.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

44.34M

Volume

8.46K

Avg. Volume

1.43M

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$13.34M

EBITDA

-$46.04M

Operating Cash Flow

-$13.18M

Capital Expenditure

$0.00

Free Cash Flow

-$13.18M

Cash & ST Invst.

$8.92M

Total Debt

$0.00

GT Biopharma Performance Analysis

GT Biopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
GT Biopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
GT Biopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -19.66-68.2%
20232023-12-31USD -5.64-71.3%
20242024-12-31USD -6.9423.1%
20252025-12-31USD -6.25-9.9%
GT Biopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-66.7%
Q32025-09-30289.1%
Q42025-12-31-577.9%
Q12026-03-3197.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$13.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$13.39M

N/A

Employees

1

N/A

Net Income

-$2.83M

-265.1%

EBITDA

-$2.77M

-257.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$8.92M

+277.3%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-4.78%

N/A

Return on Invested Capital

-1.76%

N/A

Free Cash Flow

-$2.47M

-12.1%

Operating Cash Flow

-$2.47M

-12.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SLRXSalarius Pharmaceuticals, Inc.
$0.84+29.23%
REVBRevelation Biosciences, Inc.
$1.11-1.77%
ARTLArtelo Biosciences, Inc.
$0.73-0.62%
DRMADermata Therapeutics, Inc.
$1.38+27.78%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$9.77+0.00%
NOKNokia
$10.32+0.09%
SPCXSpace Exploration Technologies
$146.15+0.10%
SMCISuper Micro Computer
$37.61+0.19%

Questions About GTBP

What is the current price of GT Biopharma?

GT Biopharma is trading at $0.30 per share.

What is the 52-week range for GT Biopharma?

Over the past 52 weeks, GT Biopharma has traded between $0.26 and $1.70.

How much debt does GT Biopharma have?

As of the most recent reporting period, GT Biopharma reported total debt of $0.00.

How much cash does GT Biopharma have on hand?

GT Biopharma reported $9.02M in cash and cash equivalents in its most recent financial results.

What is GT Biopharma’s dividend yield?

GT Biopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services